Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial

I Lang; M Inbar; G Steger; Richard Greil; Z Zvirbule; S Beslija; Z Kahan; V Taskova; B Kaufmann; CC Zielinski

Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial

I Lang, M Inbar, G Steger, Richard Greil, Z Zvirbule, S Beslija, Z Kahan, V Taskova, B Kaufmann, CC Zielinski

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

2 Citations (Web of Science)

Original language	English
Pages (from-to)	277-278
Journal	ECJ SUPPLEMENTS
Volume	7
Issue number	2
Publication status	Published - 2009
Event	15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology - Berlin, GERMANY Duration: 20 Sept 2009 → 24 Sept 2009

Cite this

Lang, I., Inbar, M., Steger, G., Greil, R., Zvirbule, Z., Beslija, S., Kahan, Z., Taskova, V., Kaufmann, B., & Zielinski, CC. (2009). Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial. ECJ SUPPLEMENTS, 7(2), 277-278.

@article{980b60c685ac4a3698e31700708ded02,

title = "Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial",

author = "I Lang and M Inbar and G Steger and Richard Greil and Z Zvirbule and S Beslija and Z Kahan and V Taskova and B Kaufmann and CC Zielinski",

year = "2009",

language = "English",

volume = "7",

pages = "277--278",

journal = "ECJ SUPPLEMENTS",

issn = "1359-6349",

number = "2",

note = "15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology ; Conference date: 20-09-2009 Through 24-09-2009",

}

Lang, I, Inbar, M, Steger, G, Greil, R, Zvirbule, Z, Beslija, S, Kahan, Z, Taskova, V, Kaufmann, B & Zielinski, CC 2009, 'Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial', ECJ SUPPLEMENTS, vol. 7, no. 2, pp. 277-278.

Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial. / Lang, I; Inbar, M; Steger, G et al.
In: ECJ SUPPLEMENTS, Vol. 7, No. 2, 2009, p. 277-278.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial

AU - Lang, I

AU - Inbar, M

AU - Steger, G

AU - Greil, Richard

AU - Zvirbule, Z

AU - Beslija, S

AU - Kahan, Z

AU - Taskova, V

AU - Kaufmann, B

AU - Zielinski, CC

PY - 2009

Y1 - 2009

M3 - Abstract (Journal)

SN - 1359-6349

VL - 7

SP - 277

EP - 278

JO - ECJ SUPPLEMENTS

JF - ECJ SUPPLEMENTS

IS - 2

T2 - 15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology

Y2 - 20 September 2009 through 24 September 2009

ER -